Which statement about anti-CCP testing compared to RF is true?

Which statement about anti-CCP testing compared to RF is true?

• A. Anti-CCP has lower specificity than RF
• B. Anti-CCP is not used in clinical practice
• C. Anti-CCP is produced by glycosylation
• D. Anti-CCP has high specificity for RA

Answer: (D)

Anti-CCP testing has high specificity for rheumatoid arthritis, which means a positive result strongly supports RA and helps distinguish it from other conditions that can cause joint symptoms. This high specificity comes from the fact that anti-CCP antibodies target citrullinated peptides, a post-translational modification that is particularly associated with RA. Because other diseases and healthy individuals less commonly have these antibodies, the test is very good at confirming RA when positive. Rheumatoid factor, by contrast, can be present in other autoimmune diseases and even in healthy older individuals, so its specificity is lower. Therefore, anti-CCP is generally more specific for RA than RF. The statement about high specificity is true. The other options are not correct because anti-CCP is indeed used in clinical practice, it is not produced by glycosylation (antibodies are produced by B cells and recognize citrullinated proteins, not a glycosylation process), and anti-CCP does not have lower specificity than RF.

Anti-CCP testing has high specificity for rheumatoid arthritis, which means a positive result strongly supports RA and helps distinguish it from other conditions that can cause joint symptoms. This high specificity comes from the fact that anti-CCP antibodies target citrullinated peptides, a post-translational modification that is particularly associated with RA. Because other diseases and healthy individuals less commonly have these antibodies, the test is very good at confirming RA when positive.

Rheumatoid factor, by contrast, can be present in other autoimmune diseases and even in healthy older individuals, so its specificity is lower. Therefore, anti-CCP is generally more specific for RA than RF.

The statement about high specificity is true. The other options are not correct because anti-CCP is indeed used in clinical practice, it is not produced by glycosylation (antibodies are produced by B cells and recognize citrullinated proteins, not a glycosylation process), and anti-CCP does not have lower specificity than RF.